Innovation-Driven

  • In 2022

    10.4 billion11

    R&D investment reached

    (RMB)

  • 1771

    授权发明专利

  • 10 +

    Global technology innovation centers

  • Leading Core technologies in various fields

    Innovative drug:focus on therapeutic areas such as oncology,immunology, central nervous system, and chronic disease, and mainly strengthencore technology platforms such as small molecule, antibody/ADC, cell therapy,and RNA

    Vaccine: platforms of bacterial vaccine + viral vaccine

    Device: three major platforms of medical cosmetology +respiratory health + professional medical care

    Research & application of OrientalLifestyle Aesthetics

    Construction of the 4D technology innovation system: five senses ofconsumers + technology innovation R&D + creative design + technologyinnovation digitalization

    Insurance: digital platformoptimizes customer experience throughout the life cycle

    Intelligent travel: full-stack self-developed L2+ intelligentdriving software and hardware solutions

    Industrial automation: leveraging digital twin, machine vision andother technologies accumulated for many years in the industry, AIGC largemodels are introduced to promote full intelligence and automation in theindustry

    New energy: from traditional energy to the upstreamextension of new energy and new materials

  • Technology innovation centers in various fields

    Fosun Pharma Global R&D Center (national level)

    JEVE Technology Center (national level)

    Wanbang Biopharma Quality Department QC Lab2 (CNAScertified)

    Fosun Cosmetics Global Innovation Center2

    Fosun Pharma North America R&D Headquarters

    Shanghai Key Laboratory of Stem Cell Therapy

    Sichuan Engineering Technology Center for IntelligentBrewing of Baijiu

    Lanvin Fabric Innovation Center

    Yuyuan Jewelry Designer Center

    Yuyuan Foods & Dining Group Innovation Center

    Academician Enterprise Research Institute

    Fosun Wine & Spirits Group Innovation Center

    ……

1 It includes scientific research investment (expensed and capitalized), but excludes digitalization expenses.

2 Application of CNAS (China National Accreditation Service for Conformity Assessment) certified laboratory is in progress

  • 13价肺炎球菌结合疫苗

    于中国境内(不包括港澳台地区)处于III期临床阶段

  • HANSIZHUANG (serplulimab injection)

    Self-developed biopharmaceutical innovative drug and the world's first monoclonal antibody drug targeting PD-1 for first-line treatment of extensive-stage small cell lung cancer
    Approved for three indications in China (excluding Hong Kong, Macau and Taiwan regions)

  • Yi Kai Da (ejilunsai injection)

    国内第1个获批上市的CAR-T细胞治疗产品
    用于二线治疗成人大B细胞淋巴瘤的上市注册申请于中国境内(不包括港澳台地区)获受理并纳入优先审评

  • 愈感

    第一个自主研发的面向敏感肌护肤品品牌-愈感问世

  • 舍得酒业

    攻关“保持基酒老酒特征的特制新材料升级处理基酒”技术方案

  • 葡萄牙保险

    My Fidelidade APP注册用户数突破100万,APP端就诊报销占比>46%,车险数字化理赔占比>48%

  • 复睿智行

    发布高性能4D毫米波雷达为核心的融合感知方案

  • 翌耀科技

    自主研发的新能源系统装备首次交付海外大客户

  • 海南矿业

    投资建设的2万吨氢氧化锂项目(一期)已正式动工,并正在积极推进非洲马里Bougouni锂矿的并购和开发

x

抖音二维码

扫一扫